Home ›
Uterine Cancer Trials ›
NCT07737795
Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer
The purpose of this study is to evaluate whether treatment with the investigational drug OK-1 in combination with paclitaxel can reduce tumor burden in patients with advanced or recurrent endometrial cancer (A/R-EC).
Trial Details
NCT ID NCT07737795
Phase PHASE2
Sponsor University of Oklahoma
Status RECRUITING
Cancer Type Uterine Cancer
Interventions
Locations (sample) Oklahoma City, Oklahoma, United States|35.46756,-97.51643
Key Eligibility Criteria
At least 18 years-of-age at the time of signature of the informed consent form (ICF). Histologically documented carcinoma of the endometrium, including endometrioid, serous, mixed adenocarcinoma, clear-cell carcinoma, or carcinosarco… Must have pre-treatment archival tissue. Measurable disease by RECIST v1.1 is required for the phase 2 portion of the study. Patients with accessible disease are eligible for the safety le…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Uterine Cancer Trials on Trialify →